BridgeBio Oncology Therapeutics (BBOT) Enters into Business Combination Agreement with Helix Acquisition Corp. II to Develop RAS and PI3Kα-Targeting Drugs
Shots:
- BBOT will reverse merge with Helix in a SPAC transaction, where combined entity - "BBOT” will be listed on Nasdaq; closing expected in Q3’25
- Upon closing, BBOT will have ~$550M cash (pre-transaction) incl. $100M in existing cash, $196M from Helix’s trust & $260M from PIPE financing. At $10.36/share, the combined entity's implied pro forma equity value is ~$949M, with BBOT shareholders rolling 100% of their equity
- Combined entity will develop BBO-8520 in the P-I (ONKORAS-101) trial for KRAS^G12C mutant NSCLC, BBO-10203 in the P-I (BREAKER-101) trial for HER2+ & HR+/HER2- breast cancer, KRAS mCRC, & KRAS mutant NSCLC, as well as BBO-11818, with first pts dosing in H1’25
Ref: BridgeBio Oncology Therapeutics | Image: BridgeBio Oncology Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
